Skip to main content
Premium Trial:

Request an Annual Quote

NextGen and Kemp Ink Protein Co-Marketing Pact

NEW YORK (GenomeWeb News) — NextGen and Kemp Biotechnologies will co-market their fee-for-service offerings, NextGen said today.
UK-based NextGen is a so-called “gene-to-protein” company, whereas Kemp provides expertise in cell culture, protein expression, and protein purification services.
Under the agreement, NextGen will offer Kemp’s pure proteins for pre-clinical research.
NextGen said the alliance will offer soluble active proteins that have been derived from gene sequences that are associated with disease in milligram to multi-gram quantities for structure determination, screening, characterization, or pre-clinical research studies.
Kemp also will transfer its transient mammalian expression technology to NextGen, which the company said will add to the range of protein-expression systems it already offers.
Financial terms of the agreement were not released.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.